Press Releases on December 11, 2022 - EIN Presswire - Press Release Distribution Service

Published on December 11, 2022 - 00:08 GMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TuSimple Holding Inc. - TSP

New York, New York--(Newsfile Corp. - December 10, 2022) - Pomerantz LLP is investigating claims on behalf of investors of TuSimple Holding Inc. ("TuSimple" or the "Company") TSP. Such investors are advised to contact Robert S. …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progyny, Inc. and Encourages Investors with ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or "the Company") PGNY for violations of the securities laws. The …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Solid Power, Inc. - SLDP

New York, New York--(Newsfile Corp. - December 10, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Solid Power, Inc. ("Solid Power" or the "Company") SLDP. Such investors are advised to contact Robert S. …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

NATIONALLY RANKED ROSEN LAW FIRM Encourages Compass Minerals International, Inc. Investors to Secure Counsel Before Important ...

NEW YORK, NY / ACCESSWIRE / December 10, 2022 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Compass Minerals International, Inc. CMP between October 31, 2017 and November 18, 2018, both dates inclusive (the …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias ...

- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D - - 9 of 12 patients who underwent stem cell transplant after achieving a response with revumenib …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

RealtySlices – Fastest Way To Raise Funds For Your Real Estate Development Project

Bellevue, Washington, United States, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Raising funds for even the best of real estate development projects is a daunting task. It is especially challenging for emerging real estate developers with some development experience …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in ...

CAMBRIDGE, Mass., Dec. 10, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today presented new data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022

New data details molecular characterization of clinical response in patients with IDH1-mutated, newly-diagnosed acute myeloid leukemia (AML) treated with TIBSOVO® (ivosidenib tablets) in combination with azacitidine in the global Phase 3 AGILE study BOSTON …

Distribution channels: Banking, Finance & Investment Industry

Published on December 11, 2022 - 00:08 GMT

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH ...

23 of 26 (88%) patients remained free of clinically significant infections caused by any of six common viruses that posoleucel targets through the Week 14 primary endpoint 3 of 26 (12%) patients had clinically significant infections despite 22 of 26 (85%) …

Distribution channels: Banking, Finance & Investment Industry